Array BioPharma withdraws NDA for US approval
March 21, 2017 at 14:12 PM EDT
Array BioPharma announced that it has withdrawn its New Drug Application (NDA) in the U.S. seeking approval of binimetinib for the treatment of NRAS mutation-positive melanoma, a rare subtype of skin cancer.
